Hamburg

• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse … Ended recruitment
  2023-508426-10-00 3 2024-06-03 Relapsed/Refractory Multiple Myeloma
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended recruitment
  2022-500571-32-00 4 2024-05-15 Early-Stage Unfavorable Classical Hodgkin Lymphoma
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi … Ended recruitment
  2022-502099-22-01 5 2024-04-29 HIV-1 Infection
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended recruitment
  2023-506011-18-00 5 2024-04-17 Vitiligo
• TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended recruitment
  2023-505722-33-00 4 2024-04-15 cholangiocarcinoma or gallbladder carcinoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr … Ended recruitment
  2024-517959-12-00 9 2024-04-11 Relapsed/refractory B cell precursor acute lymphoblastic leukemia
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended recruitment
  2023-504993-40-00 5 2024-02-14 Human immunodeficiency virus (HIV)
• Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended recruitment
  2023-505844-21-00 3 2024-02-14 juvenile idiopathic arthritis
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-dai … Ended recruitment
  2023-503531-18-00 6 2024-02-13 Prophylaxis of transplant rejection in adult kidney allograft recipien
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par … Ended recruitment
  2022-501396-62-00 5 2023-12-12 Relapsed Refractory Multiple Myeloma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505122-34-00 5 2023-12-05 Plaque Psoriasis

Showing 625–648 of 1,087 trials